Geneoscopy Inc

Geneoscopy Inc. is a St. Louis-based life sciences company specializing in noninvasive molecular diagnostics for gastrointestinal diseases. The company has developed a proprietary stool-derived eukaryotic RNA (seRNA) biomarker platform enabling precision medicine approaches to colorectal cancer screening and inflammatory bowel disease diagnosis. ColoSense, its FDA-approved flagship product, is an at-home stool test for colorectal cancer screening in average-risk individuals aged 45+, utilizing Bio-Rad's Droplet Digital PCR technology to achieve high sensitivity for cancer and advanced adenomas detection. Operating from a CLIA-certified laboratory with ~50-55 employees, Geneoscopy addresses critical gaps in colorectal cancer screening accessibility by reducing procedural barriers associated with colonoscopy. The company is expanding its diagnostic portfolio for IBD management and collaborates with major partners including Bio-Rad Laboratories and Labcorp to enhance test distribution and promote health equity in cancer prevention.